Key facts
- It has raised $2.6M; the latest was Later Stage VC ($1.4M) in Jan 2025.
- Notable investors include Hong Kong Science and Technology Parks Corporation, Shanghai Science & Technology Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Xiaomo Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Xiaomo Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xiaomo Biotech
Developer of green biomanufacturing technology focused on RNA biosynthesis. The company produces highly potent, specific, and cost-effective small interfering RNAs (siRNAs) at kilogram scale for applications including gene knockdown in mammalian cells, high-throughput RNA interference (RNAi) screening, and RNAi-based pesticides, enabling researchers and agricultural users to advance RNAi applications efficiently.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 13
- Website
- xiaomobio.com/
- Ownership
- Privately Held (backing)
Xiaomo Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xiaomo Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xiaomo Biotech in its N-PORT filings yet. We sweep new filings monthly.